The role of inositol in reproductive health

Literature review

Authors

DOI:

https://doi.org/10.18370/2309-4117.2025.81.35-42

Keywords:

inositol, myo-inositol, D-chiro-inositol, reproductive health, polycystic ovary syndrome

Abstract

This review highlights the mechanisms of action and current evidence on the effectiveness of inositol for the treatment of reproductive disorders.
The results of the studies showed that inositol plays an important role in the functioning of the reproductive system in both women and men. In women, myo-inositol (MI) acts as a second messenger of follicle-stimulating hormone in signaling pathways that regulate the proliferation and maturation of granulosa cells. MI also affects the production of anti-MГјllerian hormone, which plays a key role in the maturation of the egg, its passage through the fallopian tubes and the formation of high-quality embryos. The ovaries have a specific ratio of MI to D-chiro-inositol (DCI), which ensures their normal functioning. Excess DCI can impair the quality of oocytes and blastocysts, so its level needs to be strictly regulated.
In men, DCI affects steroidogenesis, stimulating the synthesis of androgens by Leydig cells of the testicles. It also regulates the expression of the aromatase enzyme, which leads to a decrease in estrogen synthesis. A change in the MI:DCI ratio can cause hormonal imbalance, characteristic of conditions such as polycystic ovary syndrome, female and male infertility. The use of MI and DCI in a ratio of 40:1 demonstrates the highest effectiveness in reducing all manifestations of polycystic ovary syndrome. This combination is considered first-line therapy for women with polycystic ovary syndrome and excess body weight, as it contributes to the normalization of metabolic indicators and improvement of clinical outcomes. The effectiveness of this combination of inositol stereoisomers is due to their synergistic effect: DCI reduces peripheral hyperinsulinemia, while MI restores ovulatory function. As a result, combination therapy reduces the risk of metabolic syndrome, improves hormonal balance and increases insulin sensitivity.  
Due to high efficacy, good tolerability, minimal side effects and low toxicity, inositols can be safely and widely used in these reproductive disorders.

Author Biographies

L.K. Sokolova, SI «V.P. Komisarenko Institute of Endocrinology and Metabolism of the NAMS of Ukraine», Kyiv

MD, endocrinologist, senior researcher, head of the Department of Diabetology

Y.B. Belchina, SI «V.P. Komisarenko Institute of Endocrinology and Metabolism of the NAMS of Ukraine», Kyiv

PhD, endocrinologist

References

  1. Dinicola S, Unfer V, Facchinetti F, et al. Inositols: From Established Knowledge to Novel Approaches. Int J Mol Sci. 2021 Sep 30;22(19):10575. DOI: 10.3390/ijms221910575.
  2. Sacchi S, Marinaro F, Tondelli D, et al. Modulation of gonadotrophin induced steroidogenic enzymes in granulosa cells by d-chiroinositol. Reprod Biol Endocrinol. 2016 Aug 31;14(1):52. DOI: 10.1186/s12958-016-0189-2.
  3. Zhang K, Ma Y, Luo Y, et al. Metabolic diseases and healthy aging: identifying environmental and behavioral risk factors and promoting public health. Front Public Health. 2023 Oct 13;11:1253506. DOI: 10.3389/fpubh.2023.1253506.
  4. González-Gil EM, Giménez-Legarre N, Cardon G, et al. Parental insulin resistance is associated with unhealthy lifestyle behaviours independently of body mass index in children: The Feel4Diabetes study. Eur J Pediatr. 2022 Jun;181(6):2513–22. DOI: 10.1007/s00431022-04449-0.
  5. Luo Y, Luo D, Li M, Tang B. Insulin Resistance in Pediatric Obesity: From Mechanisms to Treatment Strategies. Pediatr Diabetes. 2024 Jun 28;2024:2298306. DOI: 10.1155/2024/2298306.
  6. Tatarchuk T, Todurov I, Anagnostis P, et al. The Effect of Gastric Sleeve Resection on Menstrual Pattern and Ovulation in Premenopausal Women with Classes III–IV Obesity. Obes Surg. 2022 Mar;32(3):599–606. DOI: 10.1007/s11695-021-05820-0
  7. Laganà AS, Myers SH, Forte G, et al. Inositols in treating polycystic ovary syndrome and non-insulin dependent diabetes mellitus: now and the future. Expert Opin Drug Metab Toxicol. 2024 Jan-Feb;20(1–2):61–72. DOI: 10.1080/17425255.2024.2306851
  8. Montanino Oliva M, Buonomo G, Calcagno M, Unfer V. Effects of myo-inositol plus alpha-lactalbumin in myo-inositol-resistant PCOS women. J Ovarian Res. 2018 May 10;11(1):38. DOI: 10.1186/s13048-018-0411-2
  9. Tatarchuk TF, Kosei NV, Tutchenko TM, Glamazda MI. Optimization of ovarian function and metabolic status in syndrome of polycystic ovaries. Reproductive Endocrinology, 2020 (52), 18–22. DOI: 10.18370/2309-4117.2020.52.18-22
  10. Artini PG, Di Berardino OM, Papini F, et al. Endocrine and clinical effects of myo-inositol administration in polycystic ovary syndrome. A randomized study. Gynecol Endocrinol. 2013 Apr;29(4):375-9. DOI: 10.3109/09513590.2012.743020
  11. Costantino D, Minozzi G, Minozzi E, Guaraldi C. Metabolic and hormonal effects of myo-inositol in women with polycystic ovary syndrome: a double-blind trial. Eur Rev Med Pharmacol Sci. 2009 Mar-Apr;13(2):105-10.
  12. Nestler JE, Jakubowicz DJ, Reamer P, et al. Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome. N Engl J Med. 1999 Apr 29;340(17):1314-20. DOI: 10.1056/NEJM199904293401703.
  13. Benelli E, Del Ghianda S, Di Cosmo C, Tonacchera M. A Combined Therapy with Myo-Inositol and D-Chiro-Inositol Improves Endocrine Parameters and Insulin Resistance in PCOS Young Overweight Women. Int J Endocrinol. 2016;2016:3204083. DOI: 10.1155/2016/3204083.
  14. Regidor PA, Schindler AE, Lesoine B, Druckman R. Management of women with PCOS using myo-inositol and folic acid. New clinical data and review of the literature. Horm Mol Biol Clin Investig. 2018 Mar 2;34(2):/j/hmbci.2018.34.issue-2/hmbci-2017-0067/hmbci-2017-0067.xml. DOI: 10.1515/hmbci-2017-0067.
  15. Carlomagno G, De Grazia S, Unfer V, Manna F. Myo-inositol in a new pharmaceutical form: a step forward to a broader clinical use. Expert Opin Drug Deliv. 2012 Mar;9(3):267–71. DOI: 10.1517/17425247.2012.662953.
  16. Heimark D, McAllister J, Larner J. Decreased myo-inositol to chiro-inositol (M/C) ratios and increased M/C epimerase activity in PCOS theca cells demonstrate increased insulin sensitivity compared to controls. Endocr J. 2014;61(2):111–7. DOI: 10.1507/endocrj.ej13-0423.
  17. Unfer V, Carlomagno G, Papaleo E, et al. Hyperinsulinemia Alters Myoinositol to d-chiroinositol Ratio in the Follicular Fluid of Patients With PCOS. Reprod Sci. 2014 Jul;21(7):854–58. DOI: 10.1177/1933719113518985.
  18. Januszewski M, Issat T, Jakimiuk AA, et al. Metabolic and hormonal effects of a combined Myo-inositol and d-chiro-inositol therapy on patients with polycystic ovary syndrome (PCOS). Ginekol Pol. 2019;90(1):7–10. DOI: 10.5603/GP.2019.0002.
  19. Wojciechowska A, Osowski A, Jóźwik M, et al. Inositols’ Importance in the Improvement of the Endocrine-Metabolic Profile in PCOS. Int J Mol Sci. 2019 Nov 18;20(22):5787. DOI: 10.3390/ijms20225787
  20. Chiu TT, Rogers MS, Law EL, et al. Follicular fluid and serum concentrations of myo-inositol in patients undergoing IVF: relationship with oocyte quality. Hum Reprod. 2002 Jun;17(6):1591–6. DOI: 10.1093/humrep/17.6.1591.
  21. Gerli S, Mignosa M, Di Renzo GC. Effects of inositol on ovarian function and metabolic factors in women with PCOS: a randomized double blind placebo-controlled trial. Eur Rev Med Pharmacol Sci. 2003 Nov-Dec;7(6):151–9.
  22. Dell’Edera D, Sarlo F, Allegretti A, et al. The influence of D-chiro-inositol and D-myo-inositol in pregnant women with glucose intolerance. Biomed Rep. 2017 Aug;7(2):169–72. DOI: 10.3892/br.2017.939.
  23. Minozzi M, Costantino D, Guaraldi C, Unfer V. The effect of a combination therapy with myo-inositol and a combined oral contraceptive pill versus a combined oral contraceptive pill alone on metabolic, endocrine, and clinical parameters in polycystic ovary syndrome. Gynecol Endocrinol. 2011 Nov;27(11):920–4. DOI: 10.3109/09513590.2011.564685.
  24. Papaleo E, Unfer V, Baillargeon JP, et al. Myo-inositol in patients with polycystic ovary syndrome: a novel method for ovulation induction. Gynecol Endocrinol. 2007 Dec;23(12):700–3. DOI: 10.1080/09513590701672405.
  25. Nordio M, Proietti E. The combined therapy with myo-inositol and D-chiro-inositol reduces the risk of metabolic disease in PCOS overweight patients compared to myo-inositol supplementation alone. Eur Rev Med Pharmacol Sci. 2012 May;16(5):575-81
  26. Galazis N, Galazi M, Atiomo W. D-Chiro-inositol and its significance in polycystic ovary syndrome: a systematic review. Gynecol Endocrinol. 2011 Apr;27(4):256-62. DOI: 10.3109/09513590.2010.538099
  27. Isabella R, Raffone E. CONCERN: Does ovary need D-chiro-inositol? J Ovarian Res. 2012 May 15;5(1):14. DOI: 10.1186/1757-2215-5-14.
  28. Arya BK, Haq AU, Chaudhury K. Oocyte quality reflected by follicular fluid analysis in poly cystic ovary syndrome (PCOS): a hypothesis based on intermediates of energy metabolism. Med Hypotheses. 2012 Apr;78(4):475-8. DOI: 10.1016/j.mehy.2012.01.009.
  29. Bevilacqua A, Carlomagno G, Gerli S, et al. Results from the International Consensus Conference on myo-inositol and D-chiro-inositol in Obstetrics and Gynecology--assisted reproduction technology. Gynecol Endocrinol. 2015 Jun;31(6):441–6. DOI: 10.3109/09513590.2015.1006616.
  30. Colazingari S, Treglia M, Najjar R, Bevilacqua A. The combined therapy myo-inositol plus D-chiro-inositol, rather than D-chiro-inositol, is able to improve IVF outcomes: results from a randomized controlled trial. Arch Gynecol Obstet. 2013 Dec;288(6):1405–11. DOI: 10.1007/s00404-013-2855-3.
  31. Bhide P, Homburg R. Anti-Müllerian hormone and polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol. 2016 Nov;37:38–45. DOI: 10.1016/j.bpobgyn.2016.03.004.
  32. Nestler JE, Unfer V. Reflections on inositol(s) for PCOS therapy: steps toward success. Gynecol Endocrinol. 2015 Jul;31(7):501–5. DOI: 10.3109/09513590.2015.1054802.
  33. Dinicola S, Chiu TT, Unfer V, et al. The rationale of the myo-inositol and D-chiro-inositol combined treatment for polycystic ovary syndrome. J Clin Pharmacol. 2014 Oct;54(10):1079–92. DOI: 10.1002/jcph.362.
  34. Bevilacqua A, Dragotto J, Giuliani A, Bizzarri M. Myo-inositol and D-chiro-inositol (40:1) reverse histological and functional features of polycystic ovary syndrome in a mouse model. J Cell Physiol. 2019 Jun;234(6):9387–98. DOI: 10.1002/jcp.27623.
  35. Jiao J, Sagnelli M, Shi B, Fang Y, et al. Genetic and epigenetic characteristics in ovarian tissues from polycystic ovary syndrome patients with irregular menstruation resemble those of ovarian cancer. BMC Endocr Disord. 2019 Mar 12;19(1):30. DOI: 10.1186/s12902-019-0356-5.
  36. DeUgarte CM, Bartolucci AA, Azziz R. Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment. Fertil Steril. 2005 May;83(5):1454–60. DOI: 10.1016/j.fertnstert.2004.11.070.
  37. Diamanti-Kandarakis E, Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocr Rev. 2012 Dec;33(6):981–1030. DOI: 10.1210/er.2011-1034.
  38. Schüler-Toprak S, Ortmann O, Buechler C, Treeck O. The Complex Roles of Adipokines in Polycystic Ovary Syndrome and Endometriosis. Biomedicines. 2022 Oct 7;10(10):2503. DOI: 10.3390/biomedicines10102503.
  39. Minozzi M, Nordio M, Pajalich R. The Combined therapy myo-inositol plus D-Chiro-inositol, in a physiological ratio, reduces the cardiovascular risk by improving the lipid profile in PCOS patients. Eur Rev Med Pharmacol Sci. 2013 Feb;17(4):537–40.
  40. Genazzani AD, Santagni S, Rattighieri E, et al. Modulatory role of D-chiro-inositol (DCI) on LH and insulin secretion in obese PCOS patients. Gynecol Endocrinol. 2014 Jun;30(6):438–43. DOI: 10.3109/09513590.2014.897321.
  41. Elnashar AM. Update on obesity and assisted reproductive technology. Middle East Fertil Soc J. 2023;28 (1). DOI: 10.1186/s43043-022-00126-2

Downloads

Published

2025-12-30

How to Cite

Sokolova, L., & Belchina, Y. (2025). The role of inositol in reproductive health: Literature review. REPRODUCTIVE ENDOCRINOLOGY, (81), 35–42. https://doi.org/10.18370/2309-4117.2025.81.35-42

Issue

No. 81 (2025)

Section

Reproductology

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

    1. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.